1323 results about "Pharmacometrics" patented technology

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

A computer-implemented system for personalized health optimization constructs a confidence-weighted personal health knowledge graph (PHKG) from heterogeneous data, including wearable sensors, medical devices, lab results, medication logs, and conversational inputs. A multi-stage causal-inference stack identifies modifiable drivers of outcomes using layered methods (e.g., MI, GAM, Neural Granger, DAG-GNN), and simulates candidate interventions. A recommendation engine ranks lifestyle or pharmacologic actions using a benefit-to-friction score, selecting a personalized intervention aligned with user readiness and clinical safety constraints. Interventions may include a minimum effective dose (MED), optimal level, adaptive low-dose, or behavioral challenge. Optional modules include reinforcement learning for timing adaptation and privacy-preserving on-device inference. The system operates across domains including metabolic, cardiovascular, renal, sleep, stress, and medication response, enabling cross-condition synergy evaluation. The architecture is modular, supports runtime plug-in targets, and adapts in real time with or without continuous clinical oversight, depending on deployment.

According to the invention, there is provided a which composition is in the form of an amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of at least one biopharmaceutical drug compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. maltodextrins). Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Powder compositions may be produced by spray-drying the various components together in combination.

The present disclosure describes pharmaceutically stable high concentration liquid formulations of antibody. Such formulations comprise, in addition to the antibody, at least one anti-aggregating agent selected from arginine or lysine, buffer and poloxamer 188. In addition, the present disclosure provides high concentrated antibody formulation having high monomer, low aggregates and desirable viscosity.

The invention relates to the technical field of pharmacology and artificial intelligence, and provides a compound-target interaction prediction method and system, and the method comprises the steps: constructing a knowledge graph containing compounds, target entries and disease entities, and the correlation of the compounds, the target entries and the disease entities; inputting the knowledge graph into a multi-modal feature extraction model, and extracting topological information and internal semantic information in the knowledge graph; wherein the multi-modal feature extraction model comprises an ICD2Vec layer, a graph Transformer, a gene ontology embedding layer and an attention mechanism-based graph neural network, and the ICD2Vec layer, the graph Transformer, the gene ontology embedding layer and the attention mechanism-based graph neural network are respectively used for extracting disease semantic features, compound semantic features, protein target semantic features and topological features of a knowledge graph; performing knowledge fusion on the extracted semantic features and topological features of the knowledge graph through a feature fusion module, and obtaining a compound-target prediction probability matrix through a knowledge graph embedding method; and according to the compound-target prediction probability, performing descending sorting on the input compound-target interaction, and outputting a target recommendation list.

Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.

Compounds of formula (II) and formula (I) which are inhibitors of QPCTL and QPCT: (II) and (I) are provided herein. Also provided are pharmaceutical compositions containing this compound, as well as compounds for use in methods of treating cancer, neurodegenerative, inflammatory or autoimmune diseases. Exemplary compounds are, for example, 3-(6-fluoropyridin-3-yl)-2-[4-(4-methyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]benzonitrile (Example 1): (1), and pharmacological data are provided. TIFF2025524039000368.tif70128

The present invention addresses the problem of providing a novel compound that has a thyroid-stimulating hormone receptor antagonistic activity and is useful for the treatment of thyroid-related diseases. The present invention relates to a nitrogen-containing condensed ring compound represented by formula (A-I) or a pharmacologically acceptable salt thereof. The present invention relates to a nitrogen-containing condensed ring compound represented by formula (A-I) or a pharmacologically acceptable salt thereof. The compound or the pharmacologically acceptable salt thereof according to the present invention has an antagonistic activity against thyroid-stimulating hormone receptors and is therefore useful as a therapeutic agent for thyroid-related diseases (e.g., hyperthyroidism, Graves' disease, thyroid eye disease, and thyroid cancer) and others.

The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity.　The present invention relates to a substituted sulfonamide compound which is represented by formula (I) or a pharmacologically acceptable salt thereof. A compound according to the present invention, or a pharmacologically acceptable salt thereof, has an agonist activity against OX2R, and is useful as, for example, a therapeutic agent for sleep disorders associated with OX2R (for example, narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia associated with a physical disease, hypersomnia associated with a mental disease, hypersomnia associated with a drug or a substance, circadian rhythm sleep-wake disorders, insufficient sleep syndrome, and extended sleep).

A cosmetic containing (A) an alkali metal salt of an alkanoyl N-methyltaurine having an alkanoyl group having 8-20 carbon atoms, (B) a plant extract, (C) one or more compounds selected from the group consisting of compounds represented by general formula (1) and pharmacologically acceptable salts thereof, and (D) water (in general formula (1), R1, R3, R4 and R6 are each independently an alkyl group having 1-3 carbon atoms, R2 is an alkyl group having 1-3 carbon atoms, and R3 is an alkyl group having 1-3 carbon atoms; and R2 and R5 each independently represent a hydrogen atom or an alkyl group having 1-3 carbon atoms. ). # imgabs0 #

The invention relates to the technical field of traditional Chinese medicine research, in particular to a discovery method of a cough relieving and phlegm eliminating quality marker of cough relieving granules and the quality marker. According to the application, the cough-relieving and phlegm-eliminating drug effects of the cough-relieving granules are evaluated by virtue of concentrated ammonia water cough inducing and phenol red excretion tests, plasma pharmaceutical chemistry research of the cough-relieving granules is developed by virtue of a UHPLC-Q-Exactive Plus Orbitrap HRMS technology, and 26 prototype blood-entering components of the cough-relieving granules are analyzed and identified; through network pharmacological analysis of components entering blood, 11 potential active components for relieving cough and eliminating phlegm of the cough-relieving granules are screened, relate to 40 common targets such as IL6, TLR4, STAT3 and the like, and mainly participate in signal channels such as PI3K-Akt, HIF-1, EGFR (epidermal growth factor receptor) and the like; the seven prototype blood-entering components are quantitatively analyzed by utilizing pharmacokinetics. The three compounds of azelaic acid, caffeic acid and vanillin are used as the cough relieving and phlegm eliminating quality markers of the cough relieving granules through effectiveness, transitivity and testability. The research result is of great significance in deeply defining the pharmacodynamic material basis of the cough-relieving granules, optimizing the quality standard and promoting the clinical application of the cough-relieving granules.

The invention discloses a method for establishing a hypoperfusion cerebral infarction model, which is used for simulating a clinical cerebral infarction animal model caused by low blood pressure by adopting a method for establishing a model for combining hypotension with improved middle cerebral artery occlusion (MCAO) rats. Compared with the prior art, the technical method that existing bilateral carotid artery ligation can only simulate chronic cerebral ischemia, ischemic infarction lesions are not formed, and hypoperfusion cerebral infarction cannot be simulated is broken through, the composite method that blood pressure reduction is combined with MCAO improvement is used for the first time, and the clinical common pathological state of cerebral blood flow hypoperfusion cerebral infarction caused by hypotension is simulated. According to the invention, the pathologic process of occurrence and development of the disease and the pharmacology of the drug are researched, and the drug action mechanism is explained; a reliable animal model is provided for new drug research and development.

The invention pertains to the technical field of biomedical engineering and pharmacology and, without being limited thereto, specifically relates to a composition that enables the healing of full-thickness and chronic wounds (particularly in the foot region) observed in individuals suffering from diabetic disease.

The present invention provides a novel linker, a linker-payload, and an antibody-drug conjugate, as well as an antitumor drug. Specifically, the present invention provides an antibody-drug conjugate represented by the following general formula (I):         A-(B-L-D)a     (I) [wherein A is an antibody residue in which functional group(s) in antibody involved in binding to linker(s) is / are removed from an antibody which can target a tumor cell; B is a divalent group derived from said functional group in antibody; a is an integer of 1 to 10; D is an antitumor drug residue in which one hydrogen atom or one hydroxy group is removed from any position of an antitumor drug molecule or an analog thereof, or a derivative thereof; L is a linker which links B to D; and at least any one of D and L has one or more lactonyl group(s) as substituent(s) or protecting group(s) at any position(s)] or a pharmacologically acceptable salt thereof, or a hydrate thereof, and the like.

A system and method are herein disclosed. The system and method use a generative AI agent to analyze and identify synergistic blends of natural compounds for combination therapies by leveraging an array of specialized modes to access data from a multitude of sources including patient medical history (including test results, drug history, and imaging) to improve the efficacy of compounds, including traditional medicine, in line with combination therapy principles, aimed at: enhanced efficacy, decreased toxicity, improved dosage, and reduced drug resistance. In this way, the generative AI agent determines cross-therapeutic similarities and / or dissimilarities between pharmaceutical, naturopathic, homeopathic, and nutraceutical compounds along a plurality of compound property vectors such as efficiency, efficacy, toxicity, effects, side-effects, chemistry, pharmacology, pharmacokinetics, mechanisms of action, and pharmacodynamics, thereby enabling the proposition of cross-disciplinary and transdisciplinary therapeutic analyses and the identification of synergistic effects in combination therapies.

The invention belongs to the technical field of food functional ingredient nutriology research, and discloses application of narirutin in improving the intestinal flora homeostasis of food allergy organisms. The narirutin can adjust the relative abundance value of certain intestinal flora by adjusting the diversity of the intestinal flora of a food allergy body, improve the relative abundance of beneficial bacteria and harmful bacteria, and can influence the metabolism of short-chain fatty acid of the intestinal flora of the food allergy body, so that the food allergy body is improved. Further, the application of the narirutin in improving the intestinal flora homeostasis of food allergy organisms is realized. The application of narirutin in the research fields of nutriology, biology and pharmacology is expanded.

The invention discloses a preparation method and application of an astragalus flavonoid extract with an effect of treating systemic lupus erythematosus, and belongs to the technical field of pharmaceutical preparations. The preparation method disclosed by the invention comprises the following steps: screening components for treating systemic lupus erythematosus target protein in astragalus membranaceus by adopting reverse network pharmacology; the preparation method comprises the following steps: preparing an astragalus flavonoid substance by adopting an ultrasonic-assisted deep eutectic solvent method, and extracting the astragalus flavonoid substance by using ethyl acetate to obtain an astragalus flavonoid ethyl acetate extract; preparing magnetic nanoparticles of which the surfaces are adsorbed with the target protein; and carrying out micromolecule fishing on the astragalus flavone ethyl acetate extract by adopting the magnetic nanoparticles, so as to obtain the astragalus flavone extract with the effect of treating systemic lupus erythematosus. The radix astragali flavonoid extract prepared by the invention has a higher curative effect on systemic lupus erythematosus, and has a better effect than the existing medicine under the same dosage.

The invention discloses a traditional Chinese medicine composition for treating skin diseases and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6-12 parts of radix notoginseng, 8-15 parts of radix salviae miltiorrhizae, 10-20 parts of rhizoma chuanxiong, 8-15 parts of rhizoma curcumae longae, 15-35 parts of radix angelicae sinensis, 3-8 parts of sandalwood, 3-8 parts of fructus aurantii immaturus, 40-60 parts of ramulus cinnamomi, 8-15 parts of rhizoma corydalis, 8-15 parts of rhizoma curcumae, 2-5 parts of flos carthami, 5-12 parts of radix puerariae, 8-15 parts of radix rehmanniae, 3-8 parts of pericarpium citri reticulatae and 8-15 parts of spica prunellae. The traditional Chinese medicine composition is prepared from 3-8 parts of radix trichosanthis, 15-35 parts of tribulus terrestris, 15-35 parts of cicada slough, 5-12 parts of stiff silkworm and 8-15 parts of rhizoma drynariae. According to a multi-target collaborative mechanism, network pharmacology proves that 12 pathological pathways such as IL-17A and the like can be regulated and controlled, and the TNF-alpha inhibition rate is 89% and the barrier repair speed is increased by 2.3 times through key component combination. According to a transdermal synergistic technology, the specific surface area of the medicine reaches 8.5 m < 2 > / g through superfine grinding, a Franz test shows that the penetration amount of tanshinone is increased by 3.7 times, and the onset time is shortened to 8.3 minutes. Dual scar regulation and control: the thickness of scars in 12 weeks is reduced by half through TGF-beta3 up-regulation and alpha-SMA inhibition, and the collagen order degree is improved by 3.2 times.

The invention relates to a mechanical compression and / or co-culture microfluid device and application thereof, and belongs to the technical field of biomedical science or pharmacology, the microfluid device comprises a culture chamber and a nutrition supply chamber, the culture chamber comprises at least two compartments for accommodating cells / tissues and a porous limiting plate shared with the nutrition supply chamber, the compartments at least comprise a compression compartment for accommodating cells / tissues subjected to mechanical compression and a non-compression compartment which is not subjected to compression strength or is subjected to compression strength far lower than the compression strength of the compression compartment, and the actuating chamber drives the flexible partition plate on the bottom surface of the culture chamber to periodically deform and restore to the original shape after being in contact with the limiting plate; and at least one compartment of the nutrition supply room corresponds to the culture room. The device is free of complex alignment operation, low in manufacturing difficulty, low in cost and particularly suitable for simulating the microenvironment of cartilage tissue, the thin face shape formed by the compression compartment simulates the shape and nutrition supply mode of cartilage, and meanwhile the non-compression compartment can achieve co-culture of multiple kinds of non-compression tissue and compressed cartilage tissue.

The invention relates to application of periplocin in anti-lung adenocarcinoma drugs and a target screening method of periplocin. Periplocin can be used for preparing anti-cancer drugs for treating lung adenocarcinoma, and can inhibit proliferation, invasion and metastasis of lung adenocarcinoma cells and induce apoptosis of the lung adenocarcinoma cells. Meanwhile, the invention also provides a method for screening anti-lung adenocarcinoma related targets of periplocin by combining transcriptomics with network pharmacology, which comprises the following steps: firstly, searching effective active components and prediction action targets of periplocin through a TCMSP database, constructing network pharmacology to screen key components and targets, and then constructing and analyzing a regulatory network. Intersection genes are determined in combination with transcriptomics, and a new thought is provided for lung adenocarcinoma treatment and drug research and development.

The present disclosure provides methods of treating thyroid eye disease comprising subcutaneously administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment. Further provided herein are pharmacologically active agents, compositions, methods and / or dosing schedules for the treatment of thyroid eye disease.

The invention provides a micro-fluidic organ chip for three-dimensional cell culture. The micro-fluidic organ chip comprises a cell model loading and culturing unit, a liquid inflow-outflow unit with height difference, and an embedded inverted cone compression ring sealing unit, the cell model loading and culturing unit is constructed by overlapping at least three layers of chips up and down; and the liquid inflow-outflow unit with the height difference is constructed and formed by respectively forming liquid circulation holes which are hermetically connected through the embedded inverted conical compression ring sealing unit on at least three layers of chips. According to the invention, the cell culture space is expanded through the cell model loading and culture unit, high compatibility of cell culture is realized, and the problem of non-uniform concentration of a test substance is eliminated through the liquid inflow-outflow unit with height difference; and high-reliability miniaturized sealing design is realized through the embedded inverted cone pressing ring sealing unit, and the device can be widely applied to culture of cell models and test substance treatment and effect index detection taking toxicological and pharmacological researches as target scenes.

The present invention addresses the problem of providing a novel compound that has a thyroid-stimulating hormone receptor antagonistic activity and is useful for the treatment of thyroid-related diseases. The present invention relates to an N-substituted cyclic amide compound represented by the formula or a pharmacologically acceptable salt thereof. The compound or the pharmacologically acceptable salt thereof according to the present invention has a thyroid-stimulating hormone receptor antagonistic activity and is useful as a therapeutic agent for thyroid-related diseases (e.g., hyperthyroidism, Graves' disease, thyroid eye disease, and thyroid cancer) and others.

Disclosed are bioadaptive environments, such as immersive multi-sensory environments that respond to biofeedback from a subject within the environment, and provide interactive and synergistic visual, auditory, tactile, and olfactory stimuli. In some aspects the bioadaptive environments are designed to enhance the therapeutic benefits from states of increased neuroplasticity and non-ordinary or altered states of consciousness, including both pharmacologically induced and non-pharmacologically induced. In some aspects, the bioadaptive environments are designed to enhance the setting for and subjective experience of psychedelics. In some aspects, disclosed bioadaptive environments enhance the therapeutic benefits of psychedelics and other plasticity-inducing agents, including when used to treat mental health disorders and neurodegenerative disorders, as well as for the improvement of wellbeing.

The invention discloses a computer-aided drug dosage optimization method. The method comprises the following steps: constructing and optimizing a QSP model of a drug and a patient; defining a state space and an action space, and initializing a bidirectional model; performing bidirectional deduction on the trained bidirectional model to obtain a virtual track; forming integrated data based on the real data, the output of the QSP model and the virtual track; constructing a learning relationship between the hierarchies; a learner and a guider are trained based on the integrated data and a PPO algorithm. According to the application, PBPK / PD modeling of the medicine in bodies of different crowds is carried out through a quantitative systematic pharmacology (QSP) model, and the physiological status of the patient after taking the medicine is calculated and predicted through a formula. According to the method, the PPO algorithm is used for strategy optimization, the amplitude of strategy updating is limited, the problem that strategy updating is too large in a traditional strategy gradient method is avoided, and the efficiency of the algorithm is improved while the strategy updating stability is guaranteed.

Pharmacological compound for stimulation of the follicular unit. The pharmacological compound is for the stimulation of the follicular unit. The pharmaceutical compound has fisnasteride, minoxidil, cystine, methionine, astaxanthin, melatonin, biotin, retinol, iron, selenium, collagen, zinc, molybdenum and vitamin D.

The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.

Provided herein are compounds of Formula (II) and Formula (I), which are inhibitors of QPCTL and QPCT: (II) and (I). # imgabs0 # also provides a pharmaceutical composition comprising said compound, as well as said compound for use in a method of treating cancer, a neurodegenerative disease, an inflammatory disease, or an autoimmune disease. Exemplary compounds are, for example, 3-(6-fluoropyridin-3-yl)-2-[4-(4-methyl-4H-1, 2, 4-triazol-3-yl) piperidin-1-yl] benzonitrile (embodiment 1): (1). Pharmacological data is provided.

The invention discloses a uric acid reducing composition and a preparation method and application of plant extracts of the uric acid reducing composition, and belongs to the technical field of traditional Chinese medicine formulas and preparation. The uric acid reducing composition is prepared from the following raw materials in parts by mass: 3 to 27 parts of corn stigma, 3 to 27 parts of pericarpium citri reticulatae and 3 to 27 parts of white kidney beans. The preparation method of the plant extract comprises the following steps: pretreating the raw materials, extracting effective components, compounding according to different proportions, evaluating the in-vitro xanthine oxidase inhibition effect by using the plant extract, determining the formula compatibility of the raw materials according to quantitative pharmacology, and further determining the formula compatibility of the uric acid reducing composition. The corn stigma is treated by adopting a steam wall breaking technology, so that the extraction rate of effective components of the corn stigma is remarkably improved, and the uric acid reducing effect of the product is enhanced; the uric acid reducing food prepared on the basis of the uric acid reducing composition is safe, free of side effects and suitable for being eaten by people with high uric acid for a long time.

Systems and methods that an individual may use for disposing of unwanted pharmaceutical formulation. More specifically, systems and methods that an individual may use for disposing of unwanted pharmaceutical formulations that include receiving a disposal container including a pharmacological agent activity mitigation component and combining the unwanted pharmaceutical formulation with the pharmacological agent activity mitigation component in the disposal container are provided. The systems and method may further include a direct mail mailer for sending the disposal container and pharmacological agent activity mitigation component to the user.